Why the study?
Recent technological advances have introduced various treatment options for CTEPH, but an updated summary of current treatment approaches is needed to optimize management.
This review highlights that while pulmonary endarterectomy is the treatment of choice for CTEPH, emerging medical and interventional therapies offer options for inoperable patients.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic, progressive, debilitating, and life-threatening complication of pulmonary embolism (PE). Recent technological advances have permitted various treatment options for the treatment of CTEPH, including surgery, angioplasty, and medical treatment, depending on the location and characteristics of lesions. Pulmonary endarterectomy (PEA) is the treatment of choice for CTEPH, as it offers excellent long-term outcomes and a high probability of recovery. Moreover, various medical and interventional therapies are currently being developed for patients with inoperable CTEPH. This review mainly summarizes the current treatment approaches of CTEPH, offering more options for specialist physicians to, thus, better manage chronic thromboembolic syndromes.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: